Search Results - "E. P. PANCHENKO"

Thrombotic and hemorrhagic complications in atrial fibrillation patients, undergoing elective percutaneous coronary intervention by Krivosheeva, E N, Kropacheva, E S, Panchenko, E P, Samko, A N

“…Aim. To evaluate efficacy and safety of reduced dose of direct oral anticoagulants (DOACs) as part of triple antithrombotic therapy in AF patients, undergoing…”
Get full text

Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation) by Mironova Staroverova, A I, Panchenko, E P, Kropacheva, E S, Zemlyanskaya, O A

“…To analyze the frequency of resumption of anticoagulant therapy (ACT) after major and clinically significant bleeding among AF patients who received oral…”
Get full text

Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy "REGATТA" results) by Shakhmatova, O O, Komarov, A L, Korobkova, V V, Yarovaya, E B, Andreevskaya, M V, Shuleshova, A G, Panchenko, E P

“…Upper gastrointestinal (UGI) bleeding is a common complication of antiplatelet therapy. Data from real clinical practice that characterize the range of risk…”
Get full text

Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions by Komarov, A L, Shakhmatova, O O, Muraseeva, V G, Novikova, E S, Guskova, E V, Panchenko, E P

“…The urgency of the study is determined by the lack of data necessary in order to assess the safety of prolonged use of proton pump inhibitors (PPI) in patients…”
Get full text

Is there still room for warfarin after the appearance of direct oral anticoagulants? by Panchenko, E. P.

“…After the appearance of direct oral anticoagulants (DOAC), the use of vitamin K antagonists (VKA) has become more rare, but nevertheless, there are diseases in…”
Get full text

Choice of anticoagulant in patients with atrial fibrillation that occurred in the conditions of COVID-19 (clinical case) by Panchenko, E. P.

“…The COVID-19 epidemic is accompanied by an increase in the frequency of rhythm disturbances and, in particular, atrial fibrillation. This article is a clinical…”
Get full text

Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis by Panchenko, E. P.

“…The review is devoted to the analysis of the significance of acetylsalicylic acid (ASA) in the primary and secondary prevention of various manifestations of…”
Get full text

Antithrombotic therapy in patients with atrial fibrillation and percutaneous coronary intervention: what has changed in the guidelines in 2020? by Panchenko, E. P.

“…The article presents an analytical review of the studies aimed at determining the optimal antithrombotic therapy in patients with atrial fibrillation…”
Get full text

Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer by Panchenko, E. P.

“…The relationship of venous thromboembolic complications (VTEC) to cancer is well known. Modern recommendations for the treatment of VTEC in patients with…”
Get full text

Antithrombotic therapy of coronary heart disease: time - tested essential principles by Panchenko, E. P

“…History of antithrombotic therapy in cardiology has almost 70 years, and it is undoubtedly the importance of the achievements of Soviet scientists. The…”
Get full text

The place of dabigatran in the treatment of patients with atrial fibrillation in the light of modern recommendations by Kropacheva, E. S., Panchenko, E. P.

“…This review is devoted to the aspects of anticoagulant therapy in patients with atrial fibrillation in the light of the modern understanding of this type of…”
Get full text

Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer by Fedotkina, Yu. A., Panchenko, E. P.

“…Cancer is one of the most significant risk factors for venous thromboembolic complications (VTEC), which combines deep vein thrombosis and pulmonary embolism…”
Get full text

HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS? by E. P. PANCHENKO

“…Despite the decline in cardiovascular mortality rate in recent decades due to the widespread use of antihypertensive, hypocholesterolemic and antiplatelet…”
Get full text

Past COVID-19 infection and feasibility of transcatheter aortic valve replacement in a patient with severe aortic stenosis (a clinical case study) by Zemlyanskaya, O. A., Kurilina, E. V., Panchenko, E. P.

“…A fatal case of severe stenosis of the aortic orifice in a patient with not diagnosed in time, long-term persistent covid infection is presented. The patient…”
Get full text

Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: the position of dabigatran by Kropacheva, E. S., Panchenko, E. P.

“…This review focuses on some aspects of anticoagulant therapy in the updated clinical guidelines for atrial fibrillation of the European society of cardiology,…”
Get full text

Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA)) by Kropacheva, E. S., Krivosheeva, E. N., Panchenko, E. P.

“…Introduction . Despite the large evidence base for the use of rivaroxaban, cohort studies are interesting because shows the possibility of anticoagulant…”
Get full text

Need to determine the residual concentrations of direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter implantation of the aortic valve by Staroverova, A. I., Kropacheva, E. S., Dobrovolsky, A. B., Titaeva, E. V., Panchenko, E. P.

“…Introduction . Lengthening the period of direct oral anticoagulant (DOAC) withdrawal before intervention is not allowed. Chronic kidney disease (CKD), impaired…”
Get full text

Which scale is best to assess the risk of upper gastrointestinal bleeding in patients with stable coronary artery disease in the Russian population? by Shakhmatova, O. O., Komarov, A. L., Ergasheva, U. P., Korobkova, V. V., Minushkina, L. O., Brazhnik, V. A., Zateyshchikov, D. A., Yarovaya, E. B., Panchenko, E. P.

“…Aim. To evaluate and compare the prognostic value of various scales on the risk of upper gastrointestinal bleeding (GIB) in patients with stable coronary…”
Get full text

WHAT COULD HAVE BEEN DONE DIFFERENTLY? A PATIENT WITH ACUTE CORONARY SYNDROME by E. P. Panchenko

“…A case involving a patient with acute coronary syndrome is described, and a treatment approach is suggested…”
Get full text

PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ACTIVE ONCOLOGICAL DISEASE, RECEIVING MEDICAL ANTI-CANCER CHEMOTHERAPY IN OUTPATIENT CONDITIONS. ROLE OF APIXABAN by Fedotkina, Yu. A., Panchenko, E. P.

“…Oncological disease is one of the most important risk factors for venous thromboembolic complications (VTEC). The treatment of an already confirmed VTEC in an…”
Get full text